Clinical Trial Update: Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of fruquintinib and sintilimab as second-line therapy for gastric cancer and gastroesophageal junction ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Stomach Neoplasms | Phase 2 | Status: UNKNOWN